Metabolic profile of patients with coronary artery disease and comorbid obesity.

Authors

  • T. Maksymets
  • A. Faynyk
  • E. Sklyarov

DOI:

https://doi.org/10.26641/2307-0404.2018.1(part2).126943

Keywords:

insulin resistance, statins, obesity, coronary artery disease

Abstract

Cardiovascular diseases (CVD) are the leading cause of death worldwide. Most CVD can be prevented by  modification of such risk factors as tobacco use, obesity and unhealthy diet, physical inactivity and harmful use of alcohol. Patients with CVD or who are at high cardiovascular risk due to the presence of  risk factors such as dyslipidemia, hypertension, diabetes mellitus type 2,  need early detection and management of these states. The article describes differences between metabolic profile of patients with obesity and coronary artery disease. The study included 58 patients. They were divided into 3 groups: 1st - patients with BMI <30 and CAD, 2nd - patients with BMI>30 and CAD, and 3rd - patients with BMI>30. 1st and 2nd group of patients were treated with atorvastatin in the dose of 40 mg for 2 years, 3rd - untreated. The results indicate that significant difference was faund in the lipid profile between groups of patients treated with atorvastatin in the dose of 40 mg . Transaminases and uric acid levels were different but within the reference range. The difference was found in serum glucose, insulin and HOMA-IR between participants of the 2-nd and other groups. We observed significant insulin resistance in the group of patients with coronary heart disease, obesity, treated with atorvastatin. So, administration of atorvastatin to the patients with IHD and obesity may negatively impact carbohydrate exchange and serve as a possible cause of diabetes melitus type 2 development.

Author Biographies

T. Maksymets

Danylo Halytsky Lviv National Medical University
Department of therapy N 1 FPGE
Pekarska str., 69, Lviv, 79010, Ukraine

A. Faynyk

Danylo Halytsky Lviv National Medical University
Department of therapy N 1 FPGE
Pekarska str., 69, Lviv, 79010, Ukraine

E. Sklyarov

Danylo Halytsky Lviv National Medical University
Department of therapy N 1 FPGE
Pekarska str., 69, Lviv, 79010, Ukraine

References

Gorbas' ІM. [Ischemic heart disease: epide­miol­ogy and statistics]. Medichna gazeta «Zdorov’ya Uk­raini», [Internet]. 2015;3(1). Ukrainian. Available from: http://health-ua.com/article/15840-shemchna-hvoroba-sertcya-epdemologya--statistika

[Order of the Ministry of Health ofUkrainedated June 13, 2016 No. 564 "On Approval and Implementation of Medical-Technological Documents for the Stan­dardization of Medical Aid in the Part of the Prevention of Cardiovascular Diseases"]. [Internet]. Ukrainian. Available from: http://old.moz.gov.ua/ua/por­tal/dn_­20160613_0564.html

Catapano AL, Graham I, Backer GD, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37:2999-3058.

Aiman U, Najmi A, Khan R. Statin induced dia­betes and its clinical implications. J Pharmacol Pha­rmacother. 2014;5:181-5.

Cardiovascular diseases (CVDs) WHO media centre. [Internet]. 2017. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/

Choi H, Ford E. Prevalence of the metabolic syn­drome in individuals with hyperuricemia. Am J Med. 2007;120:442-7.

Nakagomi A, Shibui T, Kohashi K, et al. Diffe­rential Effects of Atorvastatin and Pitavastatin on Infla­mmation, Insulin Resistance, and the Carotid Intima-Me­dia Thickness in Patients with Dyslipidemia. Journal of atherosclerosis and thrombosis. 2015;22:1158-71. doi: 10.5551/jat.29520

Wild S, Roglic G Green, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;67:1739-42.

Khosla U, Zharikov S, Finch J, et al. Hype­ru­ricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739-42. doi: 10.1111/j.1523-1755.2005.00273.x

Gayoso-Diz P, Otero-González M, Xosé Rod­ri­guez-Alvarez M, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013;13:47. doi: 10.1186/1472-6823-13-47

Masanari Kuwabara. Hyperuricemia, Cardio­vascular Disease, and Hypertension. Pulse (Basel). 2016;3:242-52. doi: 10.1159/000443769

Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 2010;27:735-42. doi: 10.1016/S0140-6736(09)61965-6

How to Cite

1.
Maksymets T, Faynyk A, Sklyarov E. Metabolic profile of patients with coronary artery disease and comorbid obesity. Med. perspekt. [Internet]. 2018May4 [cited 2024Mar.29];23(1(part2):51-6. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/126943

Issue

Section

CLINICAL MEDICINE